A case is described where systemic levels of prostacyclin metabolite were measured during inhaled aerosolized prostacyclin (IAP) therapy for severe hypoxaemia in a patient with the acute respiratory distress syndrome. Comparable levels of prostacyclin metabolite have been associated with a marked platelet aggregation defect in vitro. A platelet aggregation defect was also demonstrated in vivo in this patient. Haemodynamic and gas exchange data during the IAP therapy are described.
Inhaled aerosolized prostacyclin (IAP) is gaining prominence as a selective pulmonary vasodilator (SPV) for the treatment of pulmonary hypertension and refractory hypoxaemia 1 . Because of its role as a SPV, IAP may prove to be an effective treatment adjunct in conditions such as the acute respiratory distress syndrome (ARDS) where both hypoxaemia and pulmonary hypertension may co-exist 2 .
Despite the ready acceptance of IAP therapy by critical care clinicians, the toxicity of prostacyclin when administered by the inhaled route has not been well-elucidated. A recent animal study demonstrated no evidence of pulmonary inflammation when IAP was administered for eight hours 3 . The same study also detected only very low systemic levels of prostacyclin metabolite (6-keto-prostacyclin F 1 α) during IAP administration.
In this case, arterial levels of 6-keto-prostaglandin F 1 α were measured during IAP administration for hypoxaemia in a patient with ARDS.
CASE REPORT
A 41-year-old male with ARDS (Lung injury score=3) 4 secondary to pneumonia and the systemic inflammatory response syndrome (SIRS) was commenced on IAP therapy. He required a fractional inspired oxygen concentration (FiO 2 ) of 0.8 to maintain adequate oxygenation. IAP was introduced in an attempt to reduce the possible toxic consequences of the high FiO 2 .
Method
Prostacyclin in a concentration of 10 µg/ml (Flolan, GlaxoWellcome Pty Ltd, Boronia, Australia) was delivered into the inspiratory limb of the ventilator tubing via a jet nebulizer (mass median diameter of particles 3.38 µm) in a manner previously described 2 . The dose of IAP was increased in 10 ng/kg/min increments every 30 minutes from 0 ng/kg/min to a maximum of 50 ng/kg/min to determine the optimal dose of IAP for this patient. The ventilatory minute volume was not altered during this dose-finding period of three and a half hours. Institutional ethics approval and informed consent from the patient's legal surrogate had been obtained for the administration of IAP.
Monitoring during IAP therapy included pulse oximetry, intermittent mixed venous and arterial blood gases, invasive blood pressure monitoring via a radial arterial line and invasive pulmonary arterial pressure and cardiac output measurements via a balloon-tipped, flow-directed pulmonary artery catheter. Pulmonary shunt fraction was calculated using the standard equation.
In addition, arterial levels of 6-keto-prostaglandin F 1 α were measured at each incremental change in IAP dose (i.e. every 30 minutes). Arterial blood 5 ml was collected into a 10 ml glass tube containing 500 IU heparin (in 0.5 ml) and 36 µg of acetyl salicyclic acid. The samples were immediately centrifuged and the plasma frozen at -70°C. The plasma levels of 6-keto-prostaglandin F 1 α were then determined in a 1 ml plasma sample by a radioimmunoassay technique (RIA) described by Barden and co-workers 5 .
Platelet aggregation studies in response to a challenge with adenosine diphosphate (ADP) were carried out at each incremental increase in IAP, using the technique described by Burghuber and coworkers 6 . The results are shown in Figure 1 .
Results
Mean arterial pressure (MAP) remained stable during the dose-finding period. P a O 2 improved from a baseline of 84 mmHg at 0 ng/kg/min of IAP to 110 mmHg at 50 ng/kg/min of IAP. Shunt fraction reduced from 42% to 36.6% over the same dose range of IAP. All parameters showed a trend towards baseline levels when the IAP was discontinued.
Arterial levels of 6-keto-prostaglandin F 1 α rose as the dose of IAP increased. The baseline level of 6-keto-prostaglandin F 1 α was 285 pg/ml and the maximum level measured was 647 pg/ml. In tandem with the increasing levels of 6-keto-prostaglandin F 1 α, there was a reduction in maximum platelet aggregation in response to challenge with ADP from 70% at baseline to 42% at the end of the dose-finding period.
After the dose-finding exercise described above, the patient was continued on IAP therapy at 50 ng/kg/ min. It was possible at this dose of IAP to reduce the FiO 2 while maintaining adequate oxygenation. Over the subsequent five days, however, the patient's condition deteriorated despite appropriate antibiotic and supportive therapy. He died of septic shock, unresponsive to vasopressors, eight days after the initial trial of IAP therapy.
Discussion
The findings in this case again illustrate the utility and efficacy of IAP therapy for hypoxaemia and pulmonary hypertension associated with ARDS. Systemic prostacyclin metabolite levels during IAP therapy have not previously been described. The serum levels of prostacyclin metabolite, 6-ketoprostaglandin F 1 α, demonstrated by this case are at odds with the levels obtained during IAP therapy in healthy lambs 3 . Although the levels of 6-ketoprostaglandin F 1 α were below the level of detection in the animal study, lower levels of IAP had been administered, 28 ng/kg/min compared with 50 702 P. V. VAN ng/kg/min in this patient. Also, the lambs had healthy lungs whereas the case presented had markedly abnormal lungs, which may have a higher permeability to prostacyclin. The absorbed 6-ketoprostaglandin F 1 α appeared to be associated with a platelet aggregation defect in this patient (Figure 1 ).
Anti-platelet effects have been a feature of the early trials of IAP 6, 7 . An in vitro study of platelet aggregation in response to various levels of prostacyclin using blood from normal volunteers showed that very low levels of prostacyclin (10 pg/ml) produced a significant platelet aggregation defect 8 . The case described, in addition to previous evidence 8, 9 , suggests that IAP therapy may be associated with significant serum levels of 6-keto-prostaglandin F 1 α and that this substance may induce a platelet aggregation defect. This has not proven to be an issue during clinical use of inhaled prostacyclin therapy.
Although mean pulmonary arterial pressure (MPAP) and indices of oxygenation showed a trend towards baseline levels following cessation of IAP therapy, the serum level of 6-keto-prostaglandin F 1 α continued to rise, indicating ongoing hydrolysis of prostacyclin ( Figure 1) . Also, the anti-platelet effect persisted despite cessation of IAP, due to the mediation of this effect via cyclic adenosine monophosphate.
This case demonstrated the systemic absorption of prostacyclin metabolite during IAP therapy and an associated platelet aggregation defect, and again illustrated the therapeutic features of IAP therapy.
